Hims & Hers Health, Inc. (HIMS) Stock Price & Analysis
Hims & Hers Health, Inc. (HIMS) closed at USD 29.13 on Thursday, October 22, 2026, down 0.27% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 29.21; the Oct 22, 2026 session ranged USD 27.98–29.26 on volume of 8,459,992 shares. Market capitalization is $6.80B, with a 52-week range of USD 13.74–50.99 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:38 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HIMS.md
Key facts (HIMS)
- Last four reported quarters (through Jun 30, 2026): revenue $2.58B, net income -$142M (-5.5% margin), free cash flow $61.5M (SEC filings).
- Analysts: Hold (mean 2.67 on a 1–5 scale) (15 analysts), mean target USD 31.15 (range 23–42).
- Total return with dividends: 1Y -39.9% vs S&P 500 +14.9%; 5Y +283.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD 0.06, revenue estimate $893M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (HIMS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $272M | $527M | $872M | $1.48B | $2.35B | $2.58B |
| Gross profit | $204M | $409M | $715M | $1.17B | $1.73B | — |
| Operating income | -$115M | -$68.7M | -$29.5M | $61.9M | $106M | -$155M |
| Net income | -$108M | -$65.7M | -$23.5M | $126M | $128M | -$142M |
| EPS (diluted) | -$0.58 | -$0.32 | -$0.11 | $0.53 | $0.51 | — |
| Free cash flow | — | -$33.7M | $47.0M | $198M | $57.4M | $61.5M |
| Gross margin | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% | — |
| Operating margin | -42.3% | -13.0% | -3.4% | 4.2% | 4.5% | -6.0% |
| Net margin | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% | -5.5% |
| Revenue growth | +82.8% | +93.8% | +65.5% | +69.3% | +59.0% | — |
| Cash + short-term investments | $247M | $180M | $221M | $300M | $577M | — |
| Total debt | — | — | — | $0K | $973M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (HIMS)
P/S 2.6x · EV/Sales 2.8x · P/FCF 110.4x · P/B 21.0x · FCF yield 0.91% · Earnings yield -2.09% · Net debt $524M · EV $7.32B
P/E at fiscal year-ends: Dec 2025 65.3x, Dec 2024 45.4x.
Analysts (HIMS)
Consensus Hold (mean 2.67 on a 1–5 scale), 15 analysts; mean target USD 31.15 (low 23, high 42).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | Truist Securities | Target raised | Hold | $27 → $32 |
| 2026-08-21 | Barclays | Target lowered | Overweight | $39 → $35 |
| 2026-08-11 | Citigroup | Target lowered | Neutral | $35 → $33 |
| 2026-08-11 | Deutsche Bank | Target raised | Hold | $25 → $26 |
| 2026-08-11 | B of A Securities | Target raised | Neutral | $30 → $32 |
| 2026-08-11 | TD Cowen | Target raised | Hold | $25 → $30 |
| 2026-08-11 | Morgan Stanley | Target raised | Equal-Weight | $21 → $28 |
| 2026-08-11 | Needham | Target raised | Buy | $35 → $42 |
| 2026-07-24 | Truist Securities | Target raised | Hold | $23 → $27 |
| 2026-07-23 | Citigroup | Target raised | Neutral | $28 → $35 |
| 2026-07-09 | B of A Securities | Target raised | Neutral | $36 → $37 |
| 2026-07-01 | Canaccord Genuity | Target raised | Buy | $32 → $40 |
Total return (dividends reinvested) (HIMS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -39.9% | +283.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -40.0% | +30.8% |
| Volatility (annualized) | 86.4% | 81.2% |
| Max drawdown | -70.2% (Oct 2025→Feb 2026) | -77.5% (May 2025→Feb 2026) |
HIMS revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| UNITED STATES | $621.8M | 82.6% | +15.7% |
| Non-US | $131.4M | 17.4% | +1640.9% |
| Total revenue | $753.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
HIMS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Amazon (AMZN) | “We currently host our platform, serve our customers and support our operations in the United States using Amazon Web Services ("AWS"), a provider of cloud infrastructure services, and through Partner Pharmacies, Manufacturing Suppliers, and other third-party service providers, including shipping providers and contract manufacturers.” |
| Competitor | Apple (AAPL) | “•changes in mobile operating systems, such as Apple's iOS and Google's Android, that disproportionately affect us, degrade the functionality of our mobile websites or mobile applications, require that we make costly upgrades to our technology offerings, or give preferential treatment to competitors' websites or mobile applications.” |
| Competitor | Alphabet (Google) (GOOGL) | “•changes in mobile operating systems, such as Apple's iOS and Google's Android, that disproportionately affect us, degrade the functionality of our mobile websites or mobile applications, require that we make costly upgrades to our technology offerings, or give preferential treatment to competitors' websites or mobile applications.” |
Quoted from the company's 10-K filed Feb 23, 2026.
HIMS company outlook (results filed Aug 10, 2026)
- “Hims & Hers is providing the following guidance: For the third quarter 2026, we expect: • Revenue of $880 million to $900 million. • Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.”
- “For the full year 2026, we expect: • Revenue of $3.1 billion to $3.3 billion. • Adjusted EBITDA of $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%.”
Analysts expect $892.8M for the current quarter, 0.3% above the midpoint of the company's guidance ($890.0M).
Quoted word-for-word from the SEC 8-K results press release.
HIMS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.06 | $0.07 | -13.4% | $892.8M | 11 |
| Next quarter (ends Dec 2026) | $0.11 | $0.17 | -30.5% | $954.6M | 11 |
| Current fiscal year (ends Dec 2026) | $-0.56 | $-0.13 | +331.0% | $3.21B | 11 |
| Next fiscal year (ends Dec 2027) | $0.42 | $0.62 | -32.0% | $4.00B | 11 |
Key Statistics (as of October 23, 2026 at 10:38 UTC)
| Price | USD 29.13 |
|---|---|
| Change | ▼ 0.27% (down) |
| Previous Close | USD 29.21 |
| Open | USD 28.64 |
| Day Range | USD 27.98 – 29.26 |
| 52-Week Range | USD 13.74 – 50.99 |
| Volume | 8,459,992 shares |
| Market Cap | $6.80B |
| Exchange | NYQ |
Technical Analysis (HIMS)
Nexqual's technical model rates HIMS "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:38 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.6 (neutral) |
| vs SMA50 | Below (USD 29.16) |
| MACD | -0.07 (negative) |
Analyst Ratings (HIMS)
Wall Street analysts rate HIMS "Hold" based on 15 analysts, with a mean price target of USD 31.15 (range USD 23–42), per Nexqual as of October 23, 2026 at 10:38 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 31.15 |
| High Target | USD 42 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 3 / 12 / 0 |
Earnings (HIMS)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD 0.15 |
| Revenue Estimate | $892.77M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.37 vs est -0.05 ▼ miss |
| 2026-03-31 | USD -0.4 vs est 0.03 ▼ miss |
| 2025-12-31 | USD 0.08 vs est 0.04 ▲ beat |
| 2025-09-30 | USD 0.06 vs est 0.1 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financials & Fundamentals (HIMS)
| Total Revenue | $2.58B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +38.20% |
| Gross Margin | +69.53% |
| Operating Margin | -12.75% |
| Profit Margin | -5.51% |
| ROE | -32.03% |
| Debt / Equity | 4.77 |
| Current Ratio | 0.93 |
| Total Cash | $841.05M |
| Total Debt | $1.55B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $61.55M (2.4% of revenue) |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financial Health Score (HIMS)
Nexqual rates Hims & Hers Health, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:38 UTC.
| Growth | Strong — Revenue +59% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 70%, operating -13% (last 12 months) |
| Balance Sheet | Critical — $841M cash and investments vs $1.37B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $62M (last 4 quarters to Jun 2026, SEC), slim 2.4% margin |
| Efficiency | Critical — ROE -32%, ROA -2.2% |
Ownership (HIMS)
| Insider Ownership | +4.95% |
|---|---|
| Institutional Ownership | +71.23% |
| Shares Outstanding | 224.94M |
| Float | 213.75M |
| Short % of Float | +28.22% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Leadership (HIMS)
Hims & Hers Health, Inc. is led by Andrew Dudum, Co-Founder, Chairman & CEO, per Nexqual as of October 23, 2026 at 10:38 UTC.
| Co-Founder, Chairman & CEO | Andrew Dudum |
|---|---|
| Chief Operating Officer | Mike Chi |
| Chief Technology Officer | Mohamed ElShenawy |
| Senior Vice President of Mental Health | Daniel Lieberman |
| Senior Vice President of Weight Loss | Craig Primack |
Major Backers & Investors (HIMS)
Notable institutional backers of Hims & Hers Health, Inc. include Morgan Stanley, Divisadero Street Capital Management, LP, Goldman Sachs, according to Nexqual as of October 23, 2026 at 10:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 3.18% |
| Divisadero Street Capital Management, LP | 2.67% |
| Goldman Sachs | 2.3% |
| JPMorgan | 2.12% |
| FMR, LLC | 1.92% |
| Fidelity | 1.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.76% |
| Vanguard Group | 8.93% |
| State Street | 3.62% |
| Geode Capital | 2.53% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
From Hims & Hers Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Healthcare providers, including Providers prescribing on our platform, are permitted to prescribe drugs offered on the platform for "off-label" uses (i.e., uses not approved by the FDA and not described in the product's labeling) because the FDA generally does not regulate the practice of medicine.
- We have relationships with leading health systems in the U.S. including, as of December 31, 2025, Ochsner Health, Mount Sinai Health System, Carbon Health, ChristianaCare Health System, and Hartford Healthcare to provide a clinically focused, telehealth-enabled patient care collaboration.
- Regulatory and/or legal enforcement actions by the Food and Drug Administration (the "FDA"), Department of Health and Human Services, or other international, federal, state, or foreign enforcement authorities could have material adverse consequences on our business or its operations.
- Once we have commenced commercial operations, these operations will be subject to provisions governing FDA-registered manufacturers of active pharmaceutical ingredients ("API"), as well as federal regulations regarding cGMP applicable to API manufacturers.
Partnerships
- Several cosmetics and supplement products have been developed by us in partnership with the applicable manufacturers.
- Organic growth is enhanced by sophisticated omnichannel acquisition strategies meant to target future customers with condition-specific on-ramps at profitable returns on investment.
Legal & Regulatory Risks (Item 1A, quoted)
- The healthcare and technology industries are subject to changing political, economic and regulatory influences that may affect companies like ours.
- The operations of our recently launched laboratory business could subject us to additional and evolving regulatory requirements.
- Regulation of diagnostic offerings outside the United States may also affect our laboratory operations.
- The penalties for violating the Anti-Kickback Law can be severe.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LNTH | Lantheus Holdings, Inc. | USD 100.1 | ▼ 0.14% |
| AMRX | Amneal Pharmaceuticals, Inc. | USD 20.48 | ▲ 1.39% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 80.79 | ▲ 1.37% |
| ALKS | Alkermes plc | USD 44.18 | ▲ 1.61% |
| RGC | Regencell Bioscience Holdings L | USD 9.81 | ▼ 9.17% |
| RDY | Dr. Reddy's Laboratories Ltd | USD 13.23 | ▲ 0.3% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:38 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt